Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ESRRB | O95718 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374979 | 0.88 | APP (0.46) | APPHSD17B10RAB9ANPC1TP53 | |
| SCHEMBL2374725 | 0.82 | APP (0.60) | APPHSD17B10GABRA5 | |
| SCHEMBL2373702 | 0.80 | APP (0.63) | APPKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2374131 | 0.80 | APP (0.63) | APPGABRA5ABL1 | |
| SCHEMBL2373289 | 0.79 | APP (0.67) | APPRAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL2373283 | 0.79 | APP (0.67) | APPRAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL2386945 | 0.70 | APP (0.64) | APPHSD17B10 | |
| SCHEMBL10623263 | 0.69 | GAA (0.58) | HSD17B10TP53PKMSMN1; SMN2GAA | |
| SCHEMBL2374189 | 0.69 | APP (0.65) | APP | |
| SCHEMBL2374229 | 0.69 | APP (0.65) | APPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363392-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-1999109-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2363391-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363392-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7687052-B2 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | APP, PSEN1, HTT | APP 1/4885HSD17B10 2885/4885RAB9A 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.